• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Therapeutic, Humanized Monoclonal Antibody Exhibits Broad Binding and Protective Efficacy against Acinetobacter baumannii.治疗性、人源化单克隆抗体对鲍曼不动杆菌具有广泛的结合和保护效力。
Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0008623. doi: 10.1128/aac.00086-23. Epub 2023 Feb 28.
2
The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies.鲍曼不动杆菌的荚膜多糖是治疗性被动免疫策略的一个障碍。
Infect Immun. 2017 Nov 17;85(12). doi: 10.1128/IAI.00591-17. Print 2017 Dec.
3
Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.单克隆抗体通过增强细菌清除和避免败血症来预防鲍曼不动杆菌感染。
J Infect Dis. 2017 Aug 15;216(4):489-501. doi: 10.1093/infdis/jix315.
4
A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections.一种能破坏人体生物膜的单克隆抗体增强了金黄色葡萄球菌和鲍曼不动杆菌感染的啮齿动物模型中抗生素的疗效。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00904-17. Print 2017 Oct.
5
Genomic and Phenotypic Evolution of Tigecycline-Resistant Acinetobacter baumannii in Critically Ill Patients.重症患者中替加环素耐药鲍曼不动杆菌的基因组和表型演变。
Microbiol Spectr. 2022 Feb 23;10(1):e0159321. doi: 10.1128/spectrum.01593-21. Epub 2022 Jan 19.
6
Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii.利用人免疫受体转基因小鼠产生针对耐抗菌药物鲍曼不动杆菌的保护性单克隆抗体。
Nat Commun. 2024 Sep 12;15(1):7979. doi: 10.1038/s41467-024-52357-8.
7
Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period.广泛耐药鲍曼不动杆菌的趋势及剩余治疗选择：伊朗德黑兰一项为期3年的多中心研究
Lett Appl Microbiol. 2016 Dec;63(6):466-472. doi: 10.1111/lam.12669. Epub 2016 Nov 2.
8
Evaluation the reactivity of a peptide-based monoclonal antibody derived from OmpA with drug resistant pulsotypes of Acinetobacter baumannii as a potential therapeutic approach.评估一种源自 OmpA 的基于肽的单克隆抗体与鲍曼不动杆菌耐药脉冲型的反应性，作为一种潜在的治疗方法。
Ann Clin Microbiol Antimicrob. 2022 Jun 30;21(1):30. doi: 10.1186/s12941-022-00523-5.
9
Promising targets for immunotherapeutic approaches against Acinetobacter baumannii.针对鲍曼不动杆菌的免疫治疗方法的有前景的靶标。
Microb Pathog. 2022 Dec;173(Pt A):105855. doi: 10.1016/j.micpath.2022.105855. Epub 2022 Oct 28.
10
Clinical implications of glycoproteomics for Acinetobacter baumannii.鲍曼不动杆菌糖蛋白质组学的临床意义
Expert Rev Proteomics. 2015 Feb;12(1):1-3. doi: 10.1586/14789450.2015.987756. Epub 2014 Dec 11.

引用本文的文献

1
Evaluating antibody mediated opsonophagocytosis of bacteria via lab protocol: RAW 264.7 cell phagocytosis assay.通过实验室方案评估抗体介导的细菌调理吞噬作用：RAW 264.7细胞吞噬试验。
PLoS One. 2025 Sep 9;20(9):e0331445. doi: 10.1371/journal.pone.0331445. eCollection 2025.
2
Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii.利用人免疫受体转基因小鼠产生针对耐抗菌药物鲍曼不动杆菌的保护性单克隆抗体。
Nat Commun. 2024 Sep 12;15(1):7979. doi: 10.1038/s41467-024-52357-8.
3
Anti-Acinetobacter Baumannii single-chain variable fragments provide therapeutic efficacy in an immunocompromised mouse pneumonia model.抗鲍曼不动杆菌单链可变片段在免疫抑制小鼠肺炎模型中具有治疗效果。
BMC Microbiol. 2024 Feb 10;24(1):55. doi: 10.1186/s12866-023-03080-9.
4
Clinical assays rapidly predict bacterial susceptibility to monoclonal antibody therapy.临床检测可快速预测细菌对单克隆抗体治疗的敏感性。
JCI Insight. 2024 Jan 23;9(2):e174799. doi: 10.1172/jci.insight.174799.

本文引用的文献

1
Development of a Bispecific Antibody Targeting Clinical Isolates of Acinetobacter baumannii.开发一种针对鲍曼不动杆菌临床分离株的双特异性抗体。
J Infect Dis. 2023 Apr 26;227(9):1042-1049. doi: 10.1093/infdis/jiac499.
2
An update to the database for capsular polysaccharide locus typing extends the extensive and diverse repertoire of genes found at and outside the K locus.荚膜多糖基因座分型数据库的更新扩展了 K 基因座内外广泛而多样的基因库。
Microb Genom. 2022 Oct;8(10). doi: 10.1099/mgen.0.000878.
3
Monoclonal Antibody Therapy against .针对 的单克隆抗体疗法。
Infect Immun. 2021 Sep 16;89(10):e0016221. doi: 10.1128/IAI.00162-21. Epub 2021 Jul 26.
4
Monoclonal Antibody Requires Immunomodulation for Efficacy Against Acinetobacter baumannii Infection.单克隆抗体需要免疫调节以对抗鲍曼不动杆菌感染的疗效。
J Infect Dis. 2021 Dec 15;224(12):2133-2147. doi: 10.1093/infdis/jiab265.
5
A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development.用于研究和开发的临床鲍曼不动杆菌多样化小组。
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00840-20.
6
Identification of loci for capsular polysaccharide (KL) and lipooligosaccharide outer core (OCL) synthesis in genome assemblies using curated reference databases compatible with .利用与. 兼容的经过精心整理的参考数据库，在基因组组装中鉴定荚膜多糖 (KL) 和脂寡糖外核 (OCL) 合成的基因座。
Microb Genom. 2020 Mar;6(3). doi: 10.1099/mgen.0.000339.
7
Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.单克隆抗体通过增强细菌清除和避免败血症来预防鲍曼不动杆菌感染。
J Infect Dis. 2017 Aug 15;216(4):489-501. doi: 10.1093/infdis/jix315.
8
Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia.在鲍曼不动杆菌菌血症期间，宿主的命运由先天性效应物与微生物的相互作用迅速决定。
J Infect Dis. 2015 Apr 15;211(8):1296-305. doi: 10.1093/infdis/jiu593. Epub 2014 Nov 5.
9
Treatment of Acinetobacter infections.治疗不动杆菌感染。
Expert Opin Pharmacother. 2010 Apr;11(5):779-88. doi: 10.1517/14656561003596350.

治疗性、人源化单克隆抗体对鲍曼不动杆菌具有广泛的结合和保护效力。

Therapeutic, Humanized Monoclonal Antibody Exhibits Broad Binding and Protective Efficacy against Acinetobacter baumannii.

机构信息

Department of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.

Los Angeles County-USC (LAC+USC) Medical Center, Los Angeles, California, USA.

出版信息

Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0008623. doi: 10.1128/aac.00086-23. Epub 2023 Feb 28.

DOI:10.1128/aac.00086-23
PMID:36853012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10019318/
Abstract

Acinetobacter baumannii is an extremely drug-resistant pathogen necessitating the development of new therapies. We seek to generate a cocktail of monoclonal antibodies (MAbs) that can target the full diversity of A. baumannii isolates. We have newly identified the antibody MAb5. Here, we demonstrate that MAb5 has broad binding against U.S. ( = 300) and international ( = 250) isolates (72.24% and 28.76%, respectively), likely targets O-antigen capsular carbohydrates, and exhibits protective efficacy .

摘要

鲍曼不动杆菌是一种具有极强耐药性的病原体，需要开发新的治疗方法。我们试图生成一种可以针对鲍曼不动杆菌分离株的全部多样性的单克隆抗体（MAb）混合物。我们新鉴定出了抗体 MAb5。在这里，我们证明 MAb5 对美国（ = 300）和国际（ = 250）分离株具有广泛的结合活性（分别为 72.24%和 28.76%），可能靶向 O-抗原荚膜碳水化合物，并表现出保护效力。